Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Liabilities and Shareholders Equity (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Liabilities and Shareholders Equity readings, the most recent being $825.3 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 37.7% to $825.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.0 billion, a 30.07% increase, with the full-year FY2025 number at $763.6 million, up 31.54% from a year prior.
  • Liabilities and Shareholders Equity hit $825.3 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $763.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $825.3 million in Q1 2026 to a low of $210.6 million in Q2 2022.
  • Median Liabilities and Shareholders Equity over the past 5 years was $526.3 million (2023), compared with a mean of $532.8 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: fell 25.77% in 2022 and later soared 130.0% in 2023.
  • Kiniksa Pharmaceuticals International's Liabilities and Shareholders Equity stood at $459.7 million in 2022, then rose by 14.5% to $526.3 million in 2023, then grew by 10.3% to $580.6 million in 2024, then skyrocketed by 31.54% to $763.6 million in 2025, then increased by 8.07% to $825.3 million in 2026.
  • The last three reported values for Liabilities and Shareholders Equity were $825.3 million (Q1 2026), $763.6 million (Q4 2025), and $712.3 million (Q3 2025) per Business Quant data.